Abstract
Background
Patients with advanced peripheral atherosclerotic occlusive disease who are no longer candidates for either surgical or intravascular treatment or who have undergone unsuccessful surgical revascularization may be treated with IV prostanoids.
Objective
The aim of this study was to assess the efficacy, tolerability, compliance, and cost of a new system of prostanoid administration that provides a constant plasma concentration of iloprost and maintains the efficacy of the drug while reducing the risk for adverse effects (AEs) and the overall cost of treatment compared with the actually adopted infusion system.
Methods
This open-label, nonrandomized study was conducted at the University Hospital of Catania (Catania, Italy). Patients with chronic critical ischemia who were not candidates for surgical revascularization were observed. The study population was divided into 2 groups: patients in group A were treated with a continuous 6-hour IV infusion of iloprost 0.5 to 2.0 ng/kg.min once daily for at least 14 consecutive days, and patients in group B were treated with a 20-day iloprost continuous IV infusion at a mean dosage of 25 μg/d by means of a portable elastomeric infusion system. Every 5 days the patient was admitted to the day-hospital setting to replenish the drug. Primary end points were rates of major and minor amputations and death; secondary end points were complete relief or a marked reduction of pain at rest, as reflected by discontinuation of analgesic therapy and by a decrease in the patients' complaints of pain, as well as by the satisfactory healing of ulcerations. Tolerability, compliance, and cost also were assessed.
Results
Fifty-six patients (34 men, 22 women; mean [SD] age, 67 [11] years) entered the study. Group A comprised 25 patients; group B, 31 patients. The rate of major amputation in patients at Fontaine stage IV was higher in group A (33.3%) compared with group B (20.0%). The death rate was higher in group A (4.0%) than in group B (3.2%). Pain at rest completely subsided in 37.5% of patients in group A and 68.8% of patients in group B. Trophic lesions healed in 44.4% and 73.3% of patients in groups A and B, respectively. In group A, 40.0% of patients experienced AEs (ie, hyperemia, headache, flushing) that required a reduction in dose. In group B, 6.5% of patients had hyperemia at the injection site that required a reduction in dose. Total cost wasin group B wasd €1995.60, with a mean hospital stay of 6 days. Overall, patients' quality of life, assessed as the ability to resume their normal social activities, improved.
Conclusions
In this study of patients with chronic lower-limb critical ischemia, due to the consistent blood level achieved with iloprost, 20-day iloprost continuous IV infusion at a mean dosage of 25 μg/d administered by means of a portable elastomeric infusion system was shown to be similarly or more effective than the Methods used by the most important European trials (ie, iloprost 0.5–2.0 ng/kg·min once daily for at least 14 consecutive days). Furthermore, the patients were more compliant and the cost of treatment and the length of hospitalization were reduced compared with iloprost 0.5 to 2.0 ng/kg·min once daily for at least 14 consecutive days.
Full Text
The Full Text of this article is available as a PDF (604.7 KB).
References
- 1.Dormandy J, Mahir M, Ascady G. Fate of the patient with chronic leg ischaemia. A review articleJ Cardiovasc Surg. 1989;30:50–57. [PubMed] [Google Scholar]
- 2.Fontaine R, Kim M, Kieny R. Die chirurgische behandlung der peripheren durchblutungsstorungen. Helv Chir Acta. 1954;21:499–533. [PubMed] [Google Scholar]
- 3.Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group Management of peripheral arterial disease (PAD) J Vasc Surg. 2000;31:S1–S296. [PubMed] [Google Scholar]
- 4.Dormandy JA. Prostanoid drug therapy for peripheral arterial occlusive disease— the European experience. Vasc Med. 1996;1:155–158. doi: 10.1177/1358863X9600100212. [DOI] [PubMed] [Google Scholar]
- 5.Altstaedt HO, Berzewski B, Breddin HK. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: A randomized open controlled study. Prostaglandins Leukotrienes Essent Fatty Acids. 1993;49:573–578. doi: 10.1016/0952-3278(93)90163-q. [DOI] [PubMed] [Google Scholar]
- 6.Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in Severe Leg Ischaemia Study GroupEur J Vasc Endovasc Surg. 2000;20:358–362. doi: 10.1053/ejvs.2000.1175. [DOI] [PubMed] [Google Scholar]
- 7.Saniabadi AR, Lowe GD, Belch JJ. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood. Thromb Haemostasis. 1983;50:718–721. [PubMed] [Google Scholar]
- 8.Belch JJ, Saniabadi AR, Forbes CD. Whole blood white cell aggregation: A novel technique. Thromb Res. 1987;48:631–639. doi: 10.1016/0049-3848(87)90429-4. [DOI] [PubMed] [Google Scholar]
- 9.Cirillo G, Cucinotta D, Angelini A. Peripheral haemodynamics effects of intravenous infusion of a PGI2 analogue (iloprost) in elderly patients with severe peripheral arterial occlusive disease. Ather Cardiovasc Dis. 1989;4:115–121. [Google Scholar]
- 10.Skuballa W, Vorbrüeggen H. A new route to 6a-carbacyclins: Synthesis of a stable, biologically potent prostacyclin analogue. Angnew Chem Int Ed. 1981;20:1046–1048. [Google Scholar]
- 11.Brock FE, Abri O, Baitsch G. Iloprost in the treatment of ischemic tissue lesions in diabetes. Results of a placebo-controlled multicenter study with a stable prostacyclin derivativeSchweiz Med Wochenschr. 1990;120:1477–1482. [in German] [PubMed] [Google Scholar]
- 12.Bliss B, Wilkins D, Campbell WB, for the UK Severe Limb Ischaemia Study Group Treatment of limb threatening ischaemia with intravenous Iloprost: A randomised double-blind placebo controlled study. Eur J Vasc Surg. 1991;5:511–516. doi: 10.1016/s0950-821x(05)80337-8. [DOI] [PubMed] [Google Scholar]
- 13.Norgren L, Alwmark A, Angqvist KA. A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo-controlled, randomised multicenter studyEur J Vasc Surg. 1990;4:463–467. doi: 10.1016/s0950-821x(05)80784-4. [DOI] [PubMed] [Google Scholar]
- 14.Guilmot J-L, Diot E. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin: Result of a French multicentre trial. Drug Invest. 1991;3:351–359. [Google Scholar]
- 15.Balzer K, Bechara G, Bisler H. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease—a double blind placebo controlled trial with iloprost. Int Angiol. 1991;10:229–232. [PubMed] [Google Scholar]
- 16.Pessi T, Kaukinen S, Ylitalo P. Iloprost, a prostacyclin analog in the treatment of advanced peripheral arterial disease. Vasc Surg. 1986;20:301–306. [Google Scholar]
- 17.Volteas N, Leon M, Labropoulos N. The effect of iloprost in patients with rest pain. Eur J Vasc Surg. 1993;7:654–658. doi: 10.1016/s0950-821x(05)80712-1. [DOI] [PubMed] [Google Scholar]
- 18.Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO StudyLancet. 1990;335:555–557. doi: 10.1016/0140-6736(90)90346-7. [DOI] [PubMed] [Google Scholar]
- 19.Beischer W, Dembski JC, Gruss JD. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. Dawid Study GroupVASA. 1998;27:15–19. [PubMed] [Google Scholar]
- 20.Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol. 1994;13:133–142. [PubMed] [Google Scholar]
- 21.Pibiri L, Petruzzo P, Angius D. A new infusion method for a prostacyclin analogue. Minerva Cardioangiol. 1997;45:621–625. [in Italian] [PubMed] [Google Scholar]